文献速递急性肾损伤慢性肾脏病

延迟给予螺内酯通过改善肾脏炎症预防急性肾损伤向慢性肾脏病转化

Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本研究在大鼠双侧肾缺血45分钟模型中,于缺血再灌注后24小时开始给予螺内酯5天或10天,随访5个月发现两种疗程均能预防蛋白尿、肾血流下降、肾小管间质纤维化、肾小球硬化及肥大等AKI向CKD进展的表现,10天疗程更有效,早期机制涉及减轻炎症、增加内皮素B受体表达和内皮型一氧化氮合酶活化。

要点

  • 缺血再灌注后24小时启动螺内酯可预防AKI向CKD转化。
  • 10天疗程比5天疗程更有效。
  • 早期保护机制与减轻炎症及增加内皮素B受体、eNOS活化有关。

核心结论

  • 缺血性AKI后24小时给予盐皮质激素受体阻断剂螺内酯可减轻炎症、促进组织修复,避免AKI向CKD转化,提示存在预防AKI后CKD发展的治疗窗口。

研究设计与样本

  • 雄性Wistar大鼠分为假手术组和三个双侧肾缺血45分钟组:一组不治疗,另两组于缺血再灌注后24小时开始分别给予螺内酯5天或10天,在缺血诱导后10天或5个月时评估。

主要发现

  • 随访5个月时,未治疗组出现蛋白尿、肾血流减少、肾小管间质纤维化、肾小球硬化和肾小球肥厚等AKI向CKD进展的明确证据。
  • 两种螺内酯疗程均预防了上述所有改变,其中10天疗程更有效。
  • 早期机制包括缺血再灌注后前10天内炎症减轻、内皮素B受体表达增加和内皮型一氧化氮合酶活化。

临床怎么用

  • 对于缺血性AKI患者,可考虑在损伤后24小时启动盐皮质激素受体阻断剂治疗以预防CKD进展,但需等待临床研究验证。

局限性

  • 研究为动物实验,样本量未报告,结果不能直接外推至人类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute kidney injury (AKI) is not as harmless as previously thought since it may lead to chronic kidney disease (CKD). Because most of the time ischemic AKI occurs unexpectedly, it is difficult to prevent its occurrence and there are no specific therapeutic approaches to prevent the AKI to CKD transition. We aimed to determine whether mineralocorticoid receptor blockade (MRB) in the first days after ischemia/reperfusion (IR) can prevent progression to CKD. METHODS: Four groups of male Wistar rats were included: sham and three groups of bilateral renal ischemia for 45 min, one without treatment and the other two receiving spironolactone for 5 or 10 days, starting 24 h after IR. The rats were studied at 10 days or 5 months after ischemia induction. RESULTS: After 5 months of follow-up, the untreated group exhibited clear evidence of AKI to CKD progression, such as proteinuria, reduced renal blood flow, tubulointerstitial fibrosis, glomerulosclerosis and glomerular hypertrophy. All these alterations were prevented by both spironolactone treatments initiated 24 h after IR, the 10-day treatment being more effective. Within the early mechanisms of the MRB protective effect are the reduction of inflammation and increased endothelin-B-receptor expression and endothelial nitric oxide synthase activation in the first 10 days after IR. CONCLUSIONS: We propose that MRB, administered 24 h after the ischemic injury that leads to AKI, reduces inflammation and promotes efficient tissue repair that avoids the AKI to CKD transition. These data highlight a therapeutic window to preclude CKD development after AKI.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Barrera-Chimal J, Rocha L, Amador-Martínez I, et al. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. Nephrol Dial Transplant. 2019. PMID: 30107561. doi:10.1093/ndt/gfy246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。